Results 191 to 200 of about 21,331 (238)

BTK inhibitors get a boost

Nature Reviews Drug Discovery, 2017
openaire   +4 more sources

BTK Inhibitors in Chronic Lymphocytic Leukemia

Current Hematologic Malignancy Reports, 2021
The treatment landscape of chronic lymphocytic leukemia (CLL) has dramatically changed over the last few years with the introduction of novel targeted agents. Physicians are now faced with several equally effective therapy options when treating patients with CLL.
Sameh Gaballa, Javier Pinilla-Ibarz
openaire   +2 more sources

On-Target BTK Mutations Promote Resistance to Noncovalent BTK Inhibitors

Cancer Discovery, 2022
Abstract Resistance to noncovalent BTK inhibitors is mediated by non-C481 BTK and PLCγ2 mutations.
openaire   +2 more sources

Cardiotoxicity of BTK inhibitors: ibrutinib and beyond

Expert Review of Hematology, 2022
The development of Brutons Tyrosine Kinase (BTK) inhibitors has transformed the treatment of B-cell malignancies and other non-malignant conditions. Management of the unique cardiotoxic profile of these agents requires prompt recognition and a multi-disciplinary approach.The increasing indications and addition of newer agents to clinical practice and ...
Bradley W. Christensen, Vlad G Zaha, Farrukh T. Awan   +2 more
openaire   +2 more sources

BTK Inhibitor Options Expand for CLL/SLL

Cancer Discovery, 2023
Abstract Results from ALPINE, a phase III trial, indicate that the second-generation BTK inhibitor zanubrutinib is superior to ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Besides having a better safety profile, zanubrutinib also improved progression-free survival.
openaire   +2 more sources

Discovery of quinoline-based irreversible BTK inhibitors

Bioorganic & Medicinal Chemistry Letters, 2020
Bruton tyrosine kinase (BTK) is an important target in oncology and (auto)immunity. Various BTK inhibitors have been approved or are currently in clinical development. A novel BTK inhibitor series was developed starting with a quinazoline core. Moving from a quinazoline to a quinoline core provided a handle for selectivity for BTK over EGFR and ...
Gerjan, de Bruin, Dennis, Demont, Edwin, de Zwart, Saskia, Verkaik, Niels, Hoogenboom, Bas, van de Kar, Bart, van Lith, Maaike, Emmelot-van Hoek, Michael, Gulrajani, Todd, Covey, Allard, Kaptein, Tjeerd, Barf   +11 more
openaire   +2 more sources

Loxo buys BTK inhibitor

C&EN Global Enterprise, 2017
Loxo Oncology will pay Redx Pharma $40 million for the full rights to an inhibitor of BTK, an enzyme involved in B-cell development.
openaire   +1 more source

BTK inhibitors: safety + efficacy = outcome

Blood, 2023
openaire   +3 more sources

Zweitgenerations-BTK-Inhibitor

InFo Hämatologie + Onkologie, 2023
openaire   +1 more source